Concepts (226)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Rabies Vaccines | 2 | 2017 | 106 | 1.30 | Why? |
| Dengue | 7 | 2020 | 1565 | 1.06 | Why? |
| Cicatrix | 1 | 2021 | 129 | 0.82 | Why? |
| Rabies | 2 | 2017 | 113 | 0.77 | Why? |
| Yellow Fever Vaccine | 2 | 2019 | 198 | 0.76 | Why? |
| Yellow Fever | 2 | 2019 | 231 | 0.71 | Why? |
| Daptomycin | 1 | 2018 | 64 | 0.70 | Why? |
| Toll-Like Receptor 3 | 2 | 2017 | 391 | 0.68 | Why? |
| Adjuvants, Immunologic | 2 | 2017 | 1709 | 0.68 | Why? |
| Severe Dengue | 1 | 2017 | 135 | 0.58 | Why? |
| Vancomycin | 1 | 2018 | 328 | 0.58 | Why? |
| Dengue Virus | 3 | 2018 | 910 | 0.54 | Why? |
| Ships | 1 | 2020 | 1046 | 0.46 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 1 | 2018 | 711 | 0.45 | Why? |
| Staphylococcal Infections | 1 | 2018 | 1099 | 0.37 | Why? |
| Drug Discovery | 3 | 2018 | 3092 | 0.33 | Why? |
| Bacteremia | 1 | 2018 | 1372 | 0.33 | Why? |
| Rabies virus | 2 | 2017 | 92 | 0.32 | Why? |
| Vaccination | 4 | 2021 | 19050 | 0.30 | Why? |
| Singapore | 8 | 2021 | 3641 | 0.30 | Why? |
| Immunogenicity, Vaccine | 2 | 2017 | 4624 | 0.29 | Why? |
| CD4-Positive T-Lymphocytes | 2 | 2018 | 4545 | 0.29 | Why? |
| Gastrointestinal Diseases | 1 | 2020 | 2580 | 0.29 | Why? |
| Outpatients | 1 | 2017 | 3417 | 0.26 | Why? |
| Post-Exposure Prophylaxis | 2 | 2017 | 472 | 0.24 | Why? |
| Partial Thromboplastin Time | 2 | 2021 | 436 | 0.23 | Why? |
| Primary Health Care | 1 | 2020 | 4839 | 0.23 | Why? |
| Healthy Volunteers | 2 | 2017 | 1444 | 0.22 | Why? |
| Lymphocyte Activation | 2 | 2021 | 2742 | 0.22 | Why? |
| Up-Regulation | 2 | 2020 | 2249 | 0.21 | Why? |
| Liver Abscess | 1 | 2020 | 42 | 0.21 | Why? |
| Biological Variation, Individual | 1 | 2020 | 66 | 0.21 | Why? |
| T-Lymphocytes | 4 | 2021 | 6670 | 0.20 | Why? |
| Antibodies, Neutralizing | 5 | 2021 | 25288 | 0.20 | Why? |
| Cefoxitin | 1 | 2018 | 11 | 0.20 | Why? |
| Platelet Transfusion | 2 | 2020 | 209 | 0.19 | Why? |
| Interleukin-12 Subunit p40 | 1 | 2018 | 26 | 0.19 | Why? |
| Vitamin B 12 | 1 | 2020 | 132 | 0.19 | Why? |
| Yellow fever virus | 2 | 2018 | 205 | 0.19 | Why? |
| Amikacin | 1 | 2018 | 62 | 0.19 | Why? |
| Ileal Diseases | 1 | 2018 | 47 | 0.18 | Why? |
| Thrombophilia | 2 | 2021 | 1935 | 0.18 | Why? |
| Anti-Bacterial Agents | 3 | 2020 | 10083 | 0.17 | Why? |
| Magnesium | 1 | 2020 | 290 | 0.17 | Why? |
| Neutrophil Activation | 1 | 2021 | 510 | 0.17 | Why? |
| Antibodies, Monoclonal | 1 | 2017 | 8041 | 0.17 | Why? |
| Endoplasmic Reticulum Stress | 1 | 2019 | 253 | 0.16 | Why? |
| Ustekinumab | 1 | 2018 | 216 | 0.16 | Why? |
| Micronutrients | 1 | 2020 | 310 | 0.16 | Why? |
| Antiviral Agents | 4 | 2020 | 41703 | 0.16 | Why? |
| Flavivirus | 1 | 2018 | 182 | 0.16 | Why? |
| Mycobacterium Infections, Nontuberculous | 1 | 2018 | 167 | 0.15 | Why? |
| Klebsiella Infections | 1 | 2020 | 466 | 0.15 | Why? |
| Thrombocytopenia | 2 | 2020 | 2093 | 0.14 | Why? |
| Early Termination of Clinical Trials | 1 | 2018 | 1256 | 0.14 | Why? |
| Antibodies, Viral | 6 | 2021 | 51949 | 0.14 | Why? |
| Interferon-gamma | 2 | 2021 | 2711 | 0.13 | Why? |
| Gene Expression | 3 | 2021 | 3332 | 0.13 | Why? |
| Seroconversion | 2 | 2021 | 2515 | 0.13 | Why? |
| Pneumonia, Viral | 9 | 2021 | 243684 | 0.13 | Why? |
| Open Reading Frames | 1 | 2020 | 1898 | 0.13 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.12 | Why? |
| Humans | 39 | 2021 | 930598 | 0.12 | Why? |
| Vero Cells | 3 | 2021 | 14117 | 0.12 | Why? |
| Respiratory Tract Infections | 3 | 2020 | 6817 | 0.12 | Why? |
| Bibliometrics | 1 | 2020 | 731 | 0.12 | Why? |
| Coronavirus Infections | 8 | 2020 | 253789 | 0.12 | Why? |
| Adult | 19 | 2021 | 244371 | 0.12 | Why? |
| Central Nervous System Diseases | 1 | 2017 | 410 | 0.12 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.11 | Why? |
| Cluster Analysis | 1 | 2020 | 3001 | 0.11 | Why? |
| Animals | 8 | 2021 | 78931 | 0.11 | Why? |
| Middle Aged | 19 | 2021 | 270681 | 0.11 | Why? |
| Nucleocapsid Proteins | 2 | 2020 | 3120 | 0.11 | Why? |
| BCG Vaccine | 1 | 2021 | 1137 | 0.11 | Why? |
| Epitopes | 2 | 2020 | 4113 | 0.11 | Why? |
| Cross Reactions | 2 | 2020 | 4374 | 0.10 | Why? |
| Viremia | 1 | 2017 | 1020 | 0.10 | Why? |
| Cytokines | 3 | 2021 | 15010 | 0.10 | Why? |
| Gene Expression Profiling | 2 | 2021 | 3788 | 0.10 | Why? |
| Oxygen Inhalation Therapy | 2 | 2020 | 3629 | 0.10 | Why? |
| Musculoskeletal Diseases | 1 | 2017 | 646 | 0.10 | Why? |
| Immunization Schedule | 1 | 2017 | 1305 | 0.10 | Why? |
| Crohn Disease | 1 | 2018 | 959 | 0.10 | Why? |
| Microbial Sensitivity Tests | 1 | 2018 | 2886 | 0.09 | Why? |
| Male | 19 | 2021 | 367725 | 0.09 | Why? |
| Diagnosis, Differential | 2 | 2020 | 7220 | 0.09 | Why? |
| Drug Resistance, Bacterial | 1 | 2018 | 1414 | 0.09 | Why? |
| Vaccines, Synthetic | 1 | 2021 | 3231 | 0.09 | Why? |
| Recurrence | 1 | 2018 | 3675 | 0.09 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 1261 | 0.08 | Why? |
| Female | 18 | 2021 | 380317 | 0.08 | Why? |
| Gene Expression Regulation | 1 | 2020 | 4020 | 0.08 | Why? |
| Periodicals as Topic | 1 | 2020 | 1492 | 0.08 | Why? |
| Guideline Adherence | 1 | 2020 | 2309 | 0.08 | Why? |
| Transcriptome | 1 | 2020 | 3466 | 0.08 | Why? |
| Drug Evaluation, Preclinical | 1 | 2018 | 3347 | 0.08 | Why? |
| Aged | 10 | 2021 | 215776 | 0.08 | Why? |
| B-Lymphocytes | 1 | 2020 | 4418 | 0.07 | Why? |
| Viruses | 1 | 2018 | 2238 | 0.07 | Why? |
| Vitamin D | 1 | 2020 | 2904 | 0.07 | Why? |
| Hemorrhage | 1 | 2017 | 3013 | 0.07 | Why? |
| Pandemics | 10 | 2021 | 389249 | 0.07 | Why? |
| Malaysia | 2 | 2020 | 1116 | 0.07 | Why? |
| Cause of Death | 1 | 2018 | 4823 | 0.07 | Why? |
| Disease Models, Animal | 2 | 2021 | 10998 | 0.07 | Why? |
| Mice, Transgenic | 2 | 2021 | 2739 | 0.07 | Why? |
| Age Distribution | 1 | 2013 | 3567 | 0.06 | Why? |
| Virus Diseases | 1 | 2021 | 3779 | 0.06 | Why? |
| Neutralization Tests | 1 | 2017 | 6698 | 0.06 | Why? |
| Predictive Value of Tests | 1 | 2018 | 9537 | 0.06 | Why? |
| Venous Thromboembolism | 1 | 2021 | 4273 | 0.06 | Why? |
| Immunity, Cellular | 3 | 2021 | 3614 | 0.06 | Why? |
| Asymptomatic Infections | 1 | 2021 | 7218 | 0.06 | Why? |
| Spike Glycoprotein, Coronavirus | 3 | 2021 | 37182 | 0.06 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2005 | 9706 | 0.06 | Why? |
| Treatment Outcome | 5 | 2021 | 51732 | 0.06 | Why? |
| Patient Safety | 1 | 2017 | 4885 | 0.06 | Why? |
| Literature | 1 | 2020 | 24 | 0.06 | Why? |
| Immunity, Humoral | 3 | 2021 | 4849 | 0.05 | Why? |
| Acute-Phase Reaction | 1 | 2021 | 116 | 0.05 | Why? |
| Alphavirus | 1 | 2021 | 90 | 0.05 | Why? |
| Transgenes | 1 | 2021 | 227 | 0.05 | Why? |
| Minerals | 1 | 2020 | 86 | 0.05 | Why? |
| Convalescence | 2 | 2021 | 2829 | 0.05 | Why? |
| Citric Acid Cycle | 1 | 2019 | 80 | 0.05 | Why? |
| Anticoagulants | 1 | 2021 | 9563 | 0.05 | Why? |
| Algorithms | 1 | 2017 | 7346 | 0.05 | Why? |
| Interleukin-4 | 1 | 2021 | 367 | 0.05 | Why? |
| Thigh | 1 | 2018 | 55 | 0.05 | Why? |
| Replicon | 1 | 2021 | 232 | 0.05 | Why? |
| Immunity, Innate | 1 | 2017 | 6570 | 0.05 | Why? |
| Prothrombin Time | 1 | 2021 | 434 | 0.05 | Why? |
| Young Adult | 3 | 2021 | 93724 | 0.05 | Why? |
| Masks | 1 | 2021 | 8528 | 0.05 | Why? |
| Prospective Studies | 5 | 2021 | 43301 | 0.05 | Why? |
| PubMed | 1 | 2020 | 246 | 0.05 | Why? |
| Ceftriaxone | 1 | 2020 | 365 | 0.04 | Why? |
| Encephalitis Virus, Japanese | 1 | 2018 | 63 | 0.04 | Why? |
| Genome, Viral | 1 | 2020 | 13157 | 0.04 | Why? |
| Nontuberculous Mycobacteria | 1 | 2018 | 114 | 0.04 | Why? |
| Clinical Studies as Topic | 1 | 2018 | 118 | 0.04 | Why? |
| Hyperlipidemias | 1 | 2020 | 290 | 0.04 | Why? |
| Disease Progression | 3 | 2021 | 13580 | 0.04 | Why? |
| Heart Failure | 1 | 2018 | 6638 | 0.04 | Why? |
| Immunoglobulin Fc Fragments | 1 | 2021 | 691 | 0.04 | Why? |
| Equivalence Trials as Topic | 1 | 2017 | 242 | 0.04 | Why? |
| Critical Care | 1 | 2020 | 14081 | 0.04 | Why? |
| Injections, Subcutaneous | 1 | 2018 | 647 | 0.04 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.04 | Why? |
| Sequence Deletion | 1 | 2020 | 674 | 0.04 | Why? |
| Practice Guidelines as Topic | 1 | 2020 | 15421 | 0.04 | Why? |
| Immunodominant Epitopes | 1 | 2020 | 813 | 0.04 | Why? |
| Mice | 3 | 2021 | 21357 | 0.04 | Why? |
| Public Health | 1 | 2021 | 16359 | 0.04 | Why? |
| Chemokines | 1 | 2021 | 1095 | 0.04 | Why? |
| Th1 Cells | 1 | 2021 | 1228 | 0.04 | Why? |
| Symptom Flare Up | 1 | 2018 | 432 | 0.04 | Why? |
| Time Factors | 1 | 2018 | 31397 | 0.03 | Why? |
| Klebsiella pneumoniae | 1 | 2020 | 658 | 0.03 | Why? |
| Health Personnel | 1 | 2005 | 29646 | 0.03 | Why? |
| Vaccines, Attenuated | 1 | 2019 | 952 | 0.03 | Why? |
| Antigens, Viral | 2 | 2021 | 6298 | 0.03 | Why? |
| Cricetinae | 1 | 2021 | 3344 | 0.03 | Why? |
| Prognosis | 1 | 2017 | 32490 | 0.03 | Why? |
| Reactive Oxygen Species | 1 | 2019 | 1136 | 0.03 | Why? |
| Oropharynx | 1 | 2021 | 1581 | 0.03 | Why? |
| Base Sequence | 1 | 2020 | 3581 | 0.03 | Why? |
| Morbidity | 1 | 2018 | 1426 | 0.03 | Why? |
| Dose-Response Relationship, Drug | 1 | 2021 | 3776 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.03 | Why? |
| Feasibility Studies | 1 | 2021 | 3467 | 0.03 | Why? |
| Vitamins | 1 | 2020 | 1208 | 0.03 | Why? |
| Macaca mulatta | 1 | 2021 | 3716 | 0.03 | Why? |
| Nasopharynx | 2 | 2021 | 10224 | 0.03 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.03 | Why? |
| Diagnostic Imaging | 1 | 2018 | 1044 | 0.02 | Why? |
| Phosphoproteins | 1 | 2020 | 4346 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2020 | 5440 | 0.02 | Why? |
| Blood Platelets | 1 | 2020 | 1704 | 0.02 | Why? |
| Viral Load | 2 | 2021 | 15850 | 0.02 | Why? |
| Leukocytes, Mononuclear | 1 | 2018 | 2115 | 0.02 | Why? |
| Blood Coagulation | 1 | 2021 | 2768 | 0.02 | Why? |
| Virus Replication | 2 | 2020 | 14331 | 0.02 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2018 | 5542 | 0.02 | Why? |
| Cohort Studies | 2 | 2021 | 36005 | 0.02 | Why? |
| Liver | 1 | 2021 | 4007 | 0.02 | Why? |
| Amino Acid Sequence | 1 | 2018 | 6049 | 0.02 | Why? |
| Immunologic Memory | 1 | 2018 | 3362 | 0.02 | Why? |
| Disease Susceptibility | 1 | 2019 | 4002 | 0.02 | Why? |
| Serologic Tests | 1 | 2020 | 4359 | 0.02 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2021 | 9893 | 0.02 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.02 | Why? |
| Polymerase Chain Reaction | 1 | 2020 | 6740 | 0.02 | Why? |
| Survival Analysis | 1 | 2018 | 7592 | 0.02 | Why? |
| Myocardial Infarction | 1 | 2021 | 3361 | 0.02 | Why? |
| Neutrophils | 1 | 2021 | 5476 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2021 | 9091 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.02 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2021 | 5837 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.02 | Why? |
| Models, Statistical | 1 | 2021 | 5312 | 0.02 | Why? |
| Virus Shedding | 1 | 2020 | 5834 | 0.02 | Why? |
| Cross Infection | 1 | 2005 | 8675 | 0.01 | Why? |
| Drug Repositioning | 1 | 2021 | 5683 | 0.01 | Why? |
| Magnetic Resonance Imaging | 1 | 2018 | 6551 | 0.01 | Why? |
| Case-Control Studies | 1 | 2020 | 17671 | 0.01 | Why? |
| Contact Tracing | 1 | 2021 | 8448 | 0.01 | Why? |
| Length of Stay | 1 | 2018 | 11042 | 0.01 | Why? |
| Hospitalization | 2 | 2021 | 54280 | 0.01 | Why? |
| Phylogeny | 1 | 2018 | 13341 | 0.01 | Why? |
| Incidence | 1 | 2021 | 25622 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2018 | 7330 | 0.01 | Why? |
| Hypertension | 1 | 2020 | 8895 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.01 | Why? |
| Biomarkers | 1 | 2020 | 23361 | 0.01 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 9335 | 0.01 | Why? |
| Disease Outbreaks | 1 | 2005 | 27595 | 0.01 | Why? |
| Critical Illness | 1 | 2020 | 17281 | 0.01 | Why? |
| Comorbidity | 1 | 2018 | 34796 | 0.01 | Why? |
| Quarantine | 1 | 2021 | 18418 | 0.01 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.01 | Why? |
| Risk Factors | 1 | 2021 | 71621 | 0.01 | Why? |
| Retrospective Studies | 1 | 2021 | 105322 | 0.01 | Why? |
Low's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(226)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(277)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_